产品
编 号：F621031
分子式：C18H16BCl3N2O2
分子量：409.5
分子式：C18H16BCl3N2O2
分子量：409.5
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2068818-02-8
产品详情
生物活性：
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC50= 574 nM) that acts independently of Ca2+. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs).
体外研究：
In LPS-primed primary BMDMs, NLRP3-IN-NBC6 (10 μM; 15 minutes) inhibits Imiquimod-induced IL-1β release. NLRP3-IN-NBC6 completely inhibits NLRP3-dependent IL-1β release in neutrophils (neutrophils were isolated from WT and NLRP3 KO murine bone marrow and primed with LPS followed by Nigericin treatment in the presence of 10 μM NLRP3-IN-NBC6).
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC50= 574 nM) that acts independently of Ca2+. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs).
体外研究：
In LPS-primed primary BMDMs, NLRP3-IN-NBC6 (10 μM; 15 minutes) inhibits Imiquimod-induced IL-1β release. NLRP3-IN-NBC6 completely inhibits NLRP3-dependent IL-1β release in neutrophils (neutrophils were isolated from WT and NLRP3 KO murine bone marrow and primed with LPS followed by Nigericin treatment in the presence of 10 μM NLRP3-IN-NBC6).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备